Physician profile
John B Rice
NPI 1164436952
$540.05
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $36.34 · 2021: $134 · 2022: $59.13 · 2023: $81.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $81.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $81.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $282.53 | 2019-2021 | |
| Novo Nordisk INC | $78.23 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $24.12 | 2019-2020 | |
| Flowonix Medical Incorporated | $22.79 | 2019 | |
| Shire North American Group INC | $19.98 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.36 | 2022 | |
| Lilly USA, LLC | $16.31 | 2023 | Mounjaro |
| Abbvie INC. | $15.38 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.90 | 2019 | |
| Atricure, INC. | $13.30 | 2023 | |
| Glaxosmithkline, LLC. | $12.66 | 2022 | |
| Supernus Pharmaceuticals, INC. | $11.75 | 2020 | |
| Genentech USA, INC. | $11.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.